Core variability does not affect response to interferon alpha in HBeAg negative chronic hepatitis B

Journal of Hepatology

Volumn 29, Issue 3, 1998, Pages 345-351

  Alexopoulou, Alexandra ^a   Owsianka, Ania M ^b   Kafiri, Georgia ^a   Dourakis, Spyros P ^a   Carman, William F ^b   Hadziyannis, Stephanos J ^a  

^a HIPPOKRATION HOSPITAL   (Greece)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Core variability; Hepatitis B virus; IFN alpha treatment; Pre core variant

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B CORE ANTIGEN; HEPATITIS B(E) ANTIGEN; RECOMBINANT ALPHA2B INTERFERON;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; DRUG RESPONSE; FEMALE; HEPATITIS B; HUMAN; MALE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; VIRUS CORE; VIRUS GENOME;

EID: 0032171549     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(98)80050-0     Document Type: Article

References (32)

1. Hadziyannis SJ, Bramou T, Alexopoulou A, Makris A. Immunopathogenesis and natural course of anti-HBe positive chronic hepatitis and natural course of anti-HBe positive chronic hepatitis with replicating B virus. Hollinger FB, Lemon SM, Margolis H. Viral Hepatitis and Liver Disease. 1991;673-676 Williams and Wilkins, Baltimore.
2. Carman WF, Jacyna M, Hadziyannis S, Karayiannis P, McGarvey M, Makris A, et al. Mutation preventing formation of hepatitis B antigen in patients with chronic hepatitis B infection. Lancet. ii:1989;588-591.
3. Brunetto MR, Oliveri F, Rocca G, Criscuolo D, Chiaberse E, Capaldo M, et al. Natural course and response to interferon of chronic hepatits B accompanied by antibody to hepatitis B e antigen. Hepatology. 10:1989;198-202.
4. Hadziyannis S, Bramou T, Makris A, Moussoulis G, Zignego L, Papaioannou C. Interferon alfa-2b treatment of HBeAG negative/serum positive chronic active hepatitis type B. J Hepatol. 11:1990;S133-S136.
5. Fattovich G, McIntrye G, Thursz M, Colman K, Giuliano G, Alberti A, et al. Hepatitis B precore/core variation and interferon therapy. Hepatology. 22:1995;1355-1362.
6. Naoumov NV, Thomas MG, Mason AL, Chokshi S, Bodicky CJ, Farzaneh F, et al. Genomic variations in the hepatitis B core gene: a possible influencing response to interferon alpha treatment. Gastroenterology. 108:1995;505-514.
7. Alexopoulou A, Karayiannis P, Hadziyannis SJ, Aiba N, Thomas HC. Emergence and selection of HBV variants in an anti-HBe positive patient persistently infected with quasi-species. J Hepatol. 26:1997;748-753.
8. Carman WF, Thursz M, Hadziyannis S, McIntyre G, Colman K, Gioustozi A, et al. Hepatitis B e antigen negative chronic active hepatitis: hepatitis B virus core mutations occur predominantly in known antigenic determinants. J Viral Hepat. 2:1995;77-84.
9. Ferrari C, Bertoletti A, Penna A, Cavali A, Valli A, Missale G, et al. Identification of immunodominant T cell epitopes of the hepatitis B virus nucleocapsid antigen. J Clin Invest. 88:1991;214-222.
10. Salfeld J, Plaff E, Noah M, Schaller H. Antigenic determinants and functional domains in core antigen and e antigen from hepatitis B virus. J Virol. 63:1989;798-808.
11. Akarka US, Lok ASF. Naturally occurring hepatitis B core mutations. Hepatology. 22:1995;50-60.
12. Ruiz-Moreno M, Camps T, Jimenez J, Lopez R, Castillo I, Bartolome J, et al. Factors predictive ofresponse to interferon therapy in children with chronic hepatitis B. J Hepatol. 22:1995;540-544.
13. Brunetto MR, Oliveri F, Demartini A, Calvo P, Manzini P, Cerenzia MT, et al. Treatment with interferon of chronic hepatitis B associated with antibody to hepatitis B e antigen. J Hepatol. 13:1991;8-11. (Suppl 1).
14. Perrillo RP, Sciff ER, Davis GL, Bodenheimer HC Jr, Lindsay K, Payne J, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednizone withdrawal for the treatment of chronic hepatitis B. N Engl J Med. 323:1990;295-301.
15. Knodell RG, Ishak RG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1:1981;431-435.
16. Hadziyannis SJ, Hadziyannis AS, Dourakis SP, Horsh A, Alexopoulou A, Hess G. Clinical significance of quantitative anti-HBc IgM assay in acute and chronic HBV infection. Hepatogastroenterology. 40:1993;588-592.
17. Brunetto MS, Cerenzia MT, Oliveri F, Piantino P, Randone A, Calvo PL, et al. Monitoring the natural course and response to therapy of chronic hepatitis B with an automated semi-quantitative assay for IgM anti-HBc. J Hepatol. 19:1993;431-436.
18. Hadziyannis SJ, Lieberman HM, Karvountzis GG, Shafritz DA. Analysis of liver disease, nuclear HBeAg, viral replication and hepatitis B virus DNA in liver and serum of HBeAg vs anti-HBe positive carriers of hepatitis B virus. Hepatology. 3:1983;656-662.
19. Raimondo G, Meucci G, Sardo MA, Rodinno G, Campo S, Vecchi M. Persistence of 'wild type' and 'e' minus hepatitis B virus infection in chronic healthy HBsAg/anti-HBe positive carriers. J Hepatol. 20:1994;148-151.
20. Tur-Kaspa R, Klein A, Aharonson S. Hepatitis B virus precore mutants are identical in carriers from ethnic origins and are associated with a range of liver disease severity. Hepatology. 1994;1338-1342.
21. Fattovich G, Brollo L, Alberti A, Pontisso P, Giustina G, Realdi G. Long term follow-up of anti-HBe-positive chronic active hepatitis B. Hepatology. 8:1988;1651-1654.
22. Haziyannis SJ. Hepatitis B e antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Viral Hepatitis Rev. 1:1995;7-36.
23. Pastore G, Santantonio T, Milella M, Monno L, Mariano N, Moschetta R, et al. Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon. J Hepatol. 14:1992;221-225.
24. Hadziyannis SJ, Papaioannou C, Savvas S, Manesis E, Avgidis C. Long-term alpha interferon therapy in anti-HBe positive chronic hepatitis B increases significantly the frequency of sustained response. Hepatology. 19:1994;701.
25. Fattovich G, Farci P, Rugge M, Brollo L, Mandas A, Pontisso P, et al. A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg. Hepatology. 15:1992;584-589.
26. Pawlotsky JM, Bastie A, Lonjon I, Rimiri J, Darthuy F, Soussy CJ, et al. What technique should be used for routine detection and quantification of HBV DNA in clinical samples? J Virol Methods. 65:1997;245-253.
27. Rehermann B, Pasquinelli C, Mosier SM, Chisari FV. Hepatitis B virus sequence variation of cytotoxic T lymphocyte epitopes is not common in patients with chronic HBV infection. J Clin Invest. 96:1995;1527-1534.
28. Carman WF, Boner W, Fattovich G, Colman K, Dornan ES, Thursz M, et al. Hepatitis B virus core protein mutations are concentrated in B cell epitopes in progressive disease and in T helper cell epitopes during clinical remission. J Infect Dis. 175:1997;1093-1100.
29. Bozkaya H, Ayola B, Lok ASF. High rate of mutations in the hepatitis B core gene during the immune clearance phase of chronic B virus infection. Hepatology. 24:1996;32-37.
30. Schepis F, Verucchi G, Pollicino T, Attard L, Brancatelli S, Longo G, et al. Outcome of liver disease and response to interferon treatment are not influenced by hepatitis B virus core gene variability in children with chronic type B hepatitis. J Hepatol. 26:1997;765-770.
31. Chuang WL, Omata M, Ehata T, Yokosuka O, Ito Y, Imazeki F, et al. Precore mutations and core clustering mutations in chronic hepatitis B virus infection. Gastroenterology. 104:1993;263-271.
32. Ehata T, Omata M, Yokosuka O, Hosoda K, Ohto M. Variation in codons 84-101 in core nucleotide sequence correlate with hepatocellular injury in chronic hepatitis B infection. J Clin Invest. 89:1992;332-338.